TSLP and asthma: Single blockade of TSLP, IL-25, or IL-33, which stimulate ILC2 and Th2 cells to release type 2 cytokines [25, 50, 51], decreases airway inflammation and hyperresponsiveness in murine asthma models [25, 52], and concurrent blockade of all three cytokines produces more pronounced effects [53].